Haemoglobinopathies on the Move: Is Europe ready?

A spotlight on the different policies and practices of ten EU countries

February 10, 2014

A policy report, for the first time, places a spotlight on the different policies and practices of ten EU countries. The report builds on previously described initiatives by providing updated evidence for decision makers on the need to act. It also highlights the value of cost-effective policy measures, and maps areas and countries where progress is needed. A document such this one, entitled “Haemoglobinopathies on the Move: Is Europe ready?” should be of value to European policy makers in shaping the future health, migrant and social policies of the European Union and its member states.

Despite being originally endemic among populations from Southern Europe, Africa, the Middle East and Asia, haemoglobinopathies are occurring widely across the world. Today, haemoglobin disorders can be effectively prevented, treated and managed, but experts believe that a tailored, comprehensive, holistic approach to haemoglobinopathies is not equally applied across the EU members.

This is one of the conclusions of the present report, developed by a group of experts from ENERCA and the Thalassemia International Federation (TIF), in collaboration with the International Organization for Migration (IOM), Migration Health Division, Regional Office Brussels. Novartis Farma S.p.A. sponsored this project through in-kind support services from Burson-Marsteller Brussels. The report analyses the situation country by country, presenting a specific fact sheet for each European country and a comprehensive list of key findings and conclusions.

The authors of the report hope that their findings and recommendations will encourage policy makers across Europe to address the current gaps in the management of haemoglobin disorders. It will only happen by engaging in a deeper debate on health and migration policy measures that are able to adequately respond to the rise of haemoglobinopathies in Europe and ensure equitable access to healthcare and social support, thereby contributing to improved quality and long-term costeffectiveness of healthcare delivery.

Related information

Copyright © 2002 - 2020 Enerca

Co-funded by the Health Programme of the European Union.